Posted on December 9th, 2009 by Kelley Luckstein
Half of patients with relapsed or refractory mantle-cell lymphoma achieved major responses when treated with the investigational agent temsirolimus and rituximab (Rituxan), data from an ongoing clinical study showed.
Responses persisted for almost 10 months and demonstrated durability in rituximab-refractory patients, according to Stephen M. Ansell, MD, of the Mayo Clinic in Rochester, Minn.
MedPage Today, by Charles Bankhead 12/9/09
You must be logged-in to the site to post a comment.